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Bartonella quintana 
lipopolysaccharide (LPS): structure 
and characteristics of a potent TLR4 
antagonist for in-vitro and in-vivo 
applications
Gosia Malgorzata-Miller1,2, Lena Heinbockel3, Klaus Brandenburg3, Jos W. M. van der Meer1, 
Mihai G. Netea1,2 & Leo A. B. Joosten1,2
The pattern recognition receptor TLR4 is well known as a crucial receptor during infection and 
inflammation. Several TLR4 antagonists have been reported to inhibit the function of TLR4. Both 
natural occurring antagonists, lipopolysaccharide (LPS) from Gram-negative bacteria as well as 
synthetic compounds based on the lipid A structure of LPS have been described as potent inhibitors 
of TLR4. Here, we have examined the characteristics of a natural TLR4 antagonist, isolated from 
Bartonella quintana bacterium by elucidating its chemical primary structure. We have found that this 
TLR4 antagonist is actually a lipooligosaccharide (LOS) instead of a LPS, and that it acts very effective, 
with a high inhibitory activity against triggering by the LPS-TLR4 system in the presence of a potent 
TLR4 agonist (E. coli LPS). Furthermore, we demonstrate that B. quintana LPS is not inactivated by 
polymyxin B, a classical cyclic cationic polypeptide antibiotic that bind the lipid A part of LPS, such 
as E. coli LPS. Using a murine LPS/D-galactosamine endotoxaemia model we showed that treatment 
with B. quintana LPS could improve the survival rate significantly. Since endogenous TLR4 ligands have 
been associated with several inflammatory- and immune-diseases, B. quintana LPS might be a novel 
therapeutic strategy for TLR4-driven pathologies.
The innate immune system is able to recognize multiple microbial components, including those of Gram-positive 
and Gram-negative bacteria, fungi and viruses. Recognition of Gram-negative bacteria mainly occurs via 
lipopolysaccharide (LPS), one of the major components of the outer membrane of these bacteria. The lipid A 
moiety of LPS interacts with a membrane receptor complex containing Toll-like receptor 4 (TLR4), MD-2, and 
CD14 and thereby induces proinflammatory cytokines, chemokines, and adhesion molecules. Together, these 
mediators may evoke the clinical signs of bacteria-induced sepsis1–3. Apart from microbial ligands, TLR4 is able 
to recognize endogenous ligands, such as breakdown products of extracellular matrix, alarmins, and intracellular 
proteins4–8. It has been suggested that these endogenous TLR4 ligands are important for the vicious loop during 
chronic inflammation9–11 and hence TLR4 is linked to the pathogenesis of several autoimmune diseases including 
rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, Sjogren’s syndrome, psoriasis, multiple 
sclerosis, Atherosclerosis, and autoimmune diabetes12–14. The inhibition of TLR-4 activation has been investigated 
as potential anti-inflammatory therapy for many inflammatory diseases, including rheumatoid arthritis15.
Bartonella quintana is a louse-borne Gram-negative pathogen, which has been originally described during 
World War I as the causative microbe of trench fever, a disease associated with recurrent fever and headaches. 
B. quintana bacteria colonize the louse alimentary tract enabling a single louse to infect multiple humans16–20. 
After introduction into the human host, B. quintana can persist in the normally sterile bloodstream for weeks or 
month. This remarkable, prolonged persistence in the host bloodstream demonstrates the ability of B. quintana to 
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avoid clearance by the host immune defense21. Furthermore, it has been observed that patients with B. quintana 
bacteremia do not show the classical sepsis syndrome. As an explanation for this phenomenon, overproduction 
of the anti-inflammatory cytokine interleukin-10 (IL-10) and an attenuated inflammatory cytokine profile dur-
ing B. quintana bacteremia have been proposed22. We have previously described the anti-inflammatory effect of 
B. quintana LPS. The molecule blocks TLR4 activation and it has been shown that in several in vitro and in vivo 
models B. quintana LPS can be used as a potential therapeutic agent for the treatment of rheumatoid arthritis, 
ventilation-induced lung injury (VILI), atherosclerosis and other autoinflammatory diseases15,23–25. In the present 
study, we investigated the properties of B. quintana LPS in more details, in terms of induction of cytokines (pro- 
and anti-inflammatory), the potency to block TLR4, the kinetics of TLR4 antagonism and interaction with TLRs 
and other species of LPS.
Results
Bartonella quintana LPS does not induce production of pro- or anti-inflammatory cytokines. 
The first sets of experiments were designed to investigate whether exposure to B. quintana LPS results in the 
induction of pro- or anti-inflammatory cytokines by human PBMCs. As shown in Fig. 1, B. quintana LPS itself 
does not induce the production IL-1β , TNF-α , IL-6 or IL-8. In addition, exposure for 24 h with B. quintana LPS 
did not result in the production or release of IL-1Ra, or IL-10 by human primary PBMCs (data not shown). 
However, B. quintana LPS efficiently blocks production of IL-1β , TNF-α , IL-6, IL-8 or after stimulation of human 
PBMCs with E. coli LPS, indicating the potency of B. quintana LPS as TLR4 antagonist. In addition, we performed 
dose-response experiments to examine the IC50 of B. quintana LPS for the standard dose of 10 ml E. coli LPS. 
Figure 2A shows that already 20 ng of B. quintana LPS reduced the IL-6 production. At higher concentrations of 
Figure 1. No agonistic effect of B. quintana LPS on human PBMCs. Human PBMCs were isolated from 
healthy subjects, using a standard protocol. PBMCs were pre-incubated with 100 ng/ml B. quintana LPS for 2 h, 
and thereafter 10 ng/ml purified E. coli LPS was added as indicated in the graph. Cytokines were determined 
after 24 h of culture by ELISA, IL-1β (A), TNF-α (B), IL-6 (C) and IL-8 (D). PBMCs of 6 healthy donors were 
examined. *P < 0.001, two-sided Mann-Whitney U test.
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B. quintana LPS, 5-fold or higher, a strong suppression of the IL-6 production was stated. Figure 2B demonstrated 
that B. quintana LPS revealed to have an IC50 of 37.04 ng/ml at a dose of 10 ng/ml ultra pure E. coli LPS. These 
data confirmed that LPS isolated of B. quintana is a very potent TLR4 antagonist at a low concentration23.
Prolonged blocking of TLR4 by B. quintana LPS. In order to investigate the kinetics of the bindings 
capacity of B. quintana LPS to TLR4 and whether removing of the TLR4 inhibitor has an effect on blockade 
TLR4 function, we pre-incubated human PBMCs with B. quintana LPS for 1 hour. Two different approaches 
were investigated. The first approach was that B. quintana LPS was continuously present during the exposure to 
E. coli LPS and in the second approach we removed the B. quintana LPS by thorough washing (3 times). Thereafter 
the PBMCs were exposed to E. coli LPS and cells were incubated for additional 24 h, 48 h or 72 h hours. At each 
time point the cells were microscopically checked and the supernatant was collected to measure IL-1β , IL-6, 
IL-8, or TNF-α . Figure 3 shows that B. quintana LPS blocks the cytokine production by E. coli LPS at least for a 
period of 72 h. Cytokine production by human PBMCs is reduced for more than 90% over this exposure period, 
when the B. quintana LPS is present in the culture medium. The second approach in which B. quintana LPS was 
removed after 1 hour by repeated washing, identical effects on the neutralizing capacity of B. quintana LPS were 
seen (Fig. 4): Almost complete inhibition of the E. coli LPS-induced cytokine production after 72 h culture in the 
presence of 10 ng/ml of this classical TLR4 agonist. Thus, our data show that the blocking of TLR4 by B. quintana 
LPS is strong and stable for at least 72 hours.
Rapidity of binding of B. quintana LPS to TLR4. To explore the capacity of B. quintana LPS to bind 
the TLR4 over time, we examined the minimal pre-incubation time that allows B. quintana LPS to block TLR4 
completely. Therefore we pre-incubated PBMCs with 100 ng/ml and 1000 ng/ml B. quintana LPS for 15, 30, 
45 or 60 minutes and added 10 ng/ml E. coli LPS. After 24 h the IL-6 concentrations were determined in the 
Figure 2. Dose-response of the TLR4 antagonist B. quintana LPS. Human PBMCs were isolated from healthy 
subjects, using a standard protocol. PBMCs were pre-incubated with a dose-range of B. quintana LPS (10–
1000 ng/ml) for 2 h. Thereafter, 10 ng/ml E. coli LPS was added and the PBMCs were cultured for another 24 h. 
IL-6 was determined by using ELISA (A). (B) Percentage inhibition was calculated using the IL-6 concentration 
of E. coli LPS exposure as 100%. PBMCs of 6 subjects were used in this experiment. IC50 was 37.04 ng/ml. 
*P < 0.001, two-sided Mann-Whitney U test.
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supernatants. Figure 5A shows that 15 minutes’ pre-incubation is sufficient for 100 ng/ml of B. quintana LPS to 
block TLR4 receptor. The rapid binding of B. quintana LPS to TLR4 indicates that this TLR4 inhibitor is efficient.
B. quintana LPS neutralizes TLR4 even in the presence of E. coli LPS. Since we noted that B. quintana 
LPS binds very rapidly to TLR4, we investigated the neutralizing capacity of B. quintana LPS when added together 
with E. coli LPS or even after addition of E. coli LPS to the culture medium. Figure 5B indicates that B. quintana 
LPS added together with E. coli LPS blocks the TLR4 receptor for at least 72 hours. IL-6 production due to 10 ng/ml 
E. coli LPS was completely suppressed by 10 times excess of B. quintana LPS. Remarkably, when B. quintana LPS 
was added 2 hours after the PBMC were exposed to E. coli LPS, we still noted a strong suppression of the IL-6 
production. Figure 5C reveals that even a dose of 100 ng/ml B. quintana LPS (10 times excess) blocks TLR4 for 
72 hours, in the presence of the TLR agonist.
Polymyxin B does not inactivate the antagonistic effect of B. quintana LPS. It is well known that 
polymyxin B binds to LPS from several Gram-negative microorganisms and neutralizes the activity. First, we 
compared B. quintana LPS with polymyxin B to analyze the difference in the neutralizing capacity. Figure 6A,B 
showed that B. quintana LPS is far more potent to inhibit E. coli LPS mediated TNF-α or IL-6 production by 
human PBMCs. A concentration of 100 ng/ml B. quintana LPS was equally potent as 10 μ g/ml polymyxin B to 
block 1 or 10 ng/ml of E. coli LPS. Thereafter, we investigated whether polymyxin B was able to bind and inactivate 
B. quintana LPS. Figure 6C demonstrated that after pre-incubation of B. quintana LPS with 10 μ g/ml polymyxin 
B for 2 hours, the inhibitory capacity of B. quintana LPS was still very high. As control, polymyxin B neutralized 
the E. coli LPS as expected.
B. quintana LPS showed efficacy in E. coli LPS-induced murine model of endotoxaemia. To 
explore whether B. quintana LPS can be used for in vivo studies to neutralize TLR4, we administered B. quintana 
LPS in an endotoxemia model. B. quintana LPS was injected 30 minutes before a sub-lethal dose of E. coli LPS 
was injected in combination with D-galactosamine. One single injection of B. quintana LPS revealed to be pro-
tective as can be seen in Fig. 7A,B. In contrast to the LPS/D-galactosamine group (30% survival after 10 days), 
Figure 3. Time course of TLR4 inhibition in the presence of B. quintana LPS. Human PBMCs were isolated 
from healthy subjects, using a standard protocol. PBMCs were pre-incubated with 100 ng/ml or 1000 ng/ml  
B. quintana LPS for 2 h. Thereafter 10 ng/ml purified E. coli LPS was added as indicated in the graph. Cytokines 
were determined after 24 h, 48 h or 72 h of culture by standard ELISA for IL-1β (A), TNF-α (B), IL-6 (C) and 
IL-8 (D). PBMCs of 6 healthy donors were examined. *P < 0.001, two-sided Mann-Whitney U test.
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B. quintana LPS administration had a significant higher survival rate (60%). As expected, injection of 100 μ g 
B. quintana LPS alone had no detrimental effect on the survival of the mice.
Structural analysis of B. quintana LPS. In order to elucidate the structure of B. quintana LPS we per-
formed gas liquid chromatography and mass spectrometry (GLC-MS) and electrospray ionization Fourier trans-
form ion cyclotron resonance (ESI FT-ICR) analysis. The LPS of B. quintana appears in the MS analysis with a 
molecular mass of 2438,448 Dalton. By examining fragmentation products of 30 V spectra it reveals that the sugar 
composition of B. quintana LPS contains 2 Kdo, 1 HexNAc and 2 HexN. The lipids were further characterized by 
GLC-M and the fatty acids 25-OH C26:0, 2 3-OH C16:0, 3-OH C12:0 and 3-OH C12:1 were detected. Figure 8 
showed the predicted structure of B. quintana LPS and it reveals that the TLR4 antagonist is actually a lipooligo-
saccharide (LOS).
To determine the aggregate structure of B. quintana LPS, small-angle X-ray scattering (SAXS) at the Hamburg 
synchrotron source PETRA was applied. For this, LPS at a concentration of 1 mg/50 μ l was analyzed at two 
temperatures 20 and 40 °C (Fig. 9). The scattering patterns are indicative of a main maximum at d = 6.67 and 
6.29 nm for 20 and 40 °C, respectively, and further reflections each at d/2, d/3, and d/5, which can be assigned to 
a multi-lamellar aggregate structure of the LPS dispersion.
Discussion
Here we described the in-vitro and in-vivo characteristics of the natural TLR4 antagonist B. quintana LPS. LPS 
of B. quintana appears to be a very potent, rapidly binding TLR4 blocker of a potent TLR4 agonist (E. coli LPS). 
In addition, the blockade of TLR4 is prolonged: at least 72 h after exposure to human PBMCs the effect persists. 
Since TLR4 activation is associated with many inflammatory and autoimmune diseases, B. quintana LPS might 
be considered a new therapeutic strategy for TLR4-driven pathology.
Bartonella quintana is an emerging Gram-negative pathogen, which may cause endocarditis, cerebral abscess 
and bacillary angiomatosis usually with the absence of septic shock in humans. Nowadays, the B. quintana infec-
tion can be found in homeless people, mainly due to body lice26. It has been reported in the past that LPS, isolated 
Figure 4. Time course of the TLR4 inhibitor after removal of the B. quintana LPS. Human PBMCs were 
isolated from healthy subjects, using a standard protocol. PBMCs were pre-incubated with 100 ng/ml or 
1000 ng/ml B. quintana LPS for 2 h. Thereafter the PBMCs were extensively washed (3 times) to removed the 
non-bound B. quintana LPS. After the washing step, 10 ng/ml purified E. coli LPS was added. Cytokines were 
determined after 24 h, 48 h or 72 h of culture by standard ELISA for IL-1β (A), TNF-α (B), IL-6 (C) and IL-8 (D). 
PBMCs of 6 healthy donors were examined. *P < 0.001, two-sided Mann-Whitney U test.
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from B. quintana is able to induce proinflammatory cytokines when injected in rats27. This is disagreement with 
our results, in which highly purified B. quintana LPS showed no induction of cytokines, neither at the protein level 
nor at the level of gene transcription23. The main difference between our results and those previously reported by 
Matera et al., is the purity of B. quintana LPS. Due to contamination in the crude B. quintana extract, predomi-
nantly peptidoglycan-driven stimulation of cells through TLR2 ligations may occur. It revealed that Matera et al. 
used only a single isolation step to obtain B. quintana LPS (only the first step in our isolation and purification 
procedure of ultrapure B. quintana LPS). It is very likely that this crude preparation of B. quintana LPS activates 
human PBMCs in a TLR2-dependent pathway since peritoneal macrophages obtained from TLR2ko mice did not 
respond crude B. quintana LPS in vitro, in contrast to wild type mice (data not shown).
Here we described the structure of B. quintana LPS for the first time. It revealed that B. quintana LPS has 5 
fatty acid tails, two of C12, two of C16 and one very long C26 (Fig. 8). It has been shown previously that LPS 
structures with 4 fatty acid chains are endotoxically inactive28. However, B. quintana LPS consists of 5 fatty acids 
and still is acts as a very potent TLR4 antagonist. This is in line with several other reports demonstrating that LPS 
originated from Gram-negative bacteria, such as Bradyrhizobium elkanii consists of 5 fatty acids tails and reveals 
to have antagonistic properties29,30. Studies using small angle X-ray scattering (SAXS) technology indicated that 
this particular LPS has a multilamellar structure. The data for the aggregate structure of LPS from B. quintana, 
Figure 5. Kinetics of the B. quintana LPS to block the TLR4. Human PBMCs were isolated from healthy 
subjects, using a standard protocol. (A) PBMCs were pre-incubated with 100 ng/ml or 1000 ng/ml B. quintana 
LPS for different times before E. coli LPS was added to the culture medium. After 1 hour, 45, 30 and 15 minutes 
PBMC were exposed to 10 ng/ml E. coli LPS for 24 h. (B) B. quintana LPS was added together with E. coli LPS, 
thereafter the PBMCs were cultured for additional 24 h, 48 h or 72 h. C, B. quintana LPS was added in a range 
before (− 2 h) and after (+ 2 h) the cells were exposed to 10 ng/ml E. coli LPS. IL-6 was determined by using 
ELISA. PBMCs of 4 subjects were used in this experiment. *P < 0.001, two-sided Mann-Whitney U test.
www.nature.com/scientificreports/
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Figure 6. Comparison and interaction of B. quintana LPS with polymixin B. Human PBMCs were isolated 
from healthy subjects, using a standard protocol. (A,B) PMBCs were exposed to a dose range of E. coli LPS 
(0.0001 to 10 ng/ml) in the presence or absence of B. quintana LPS (100 and 500 ng/ml) or polymixin (B) (3 and 
10 μ g/ml). TNF-α and IL-6 were determined with ELISA. (C) B. quintana LPS (100 ng/ml or 1000 ng/ml) was 
pre-incubated with 10 μ g/ml polymyxin B for 2 h. Thereafter control medium, B. quintana LPS, polymyxin (B) 
B. quintana LPS + polymyxin B were added to the PBMCs for 2 h and thereafter the cells were washed 3 times 
with warm RPMI 1640 medium. After washing, RPMI 1640 medium or E. coli LPS (10 ng/ml) was added and 
the PBMCs were incubated for 24 h. IL-6 was determined by using ELISA. PBMCs of 4 subjects were used in 
this experiment. *P < 0.001, two-sided Mann-Whitney U test.
www.nature.com/scientificreports/
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a multilamellar organization, are characteristic for bioinactive structures of endotoxins similar as described by 
Brandenburg et al. and Schromm et al.31,32. In this kind of aggregate structure, the binding epitopes in LPS to 
the TLR4 receptor necessary for cell signaling are hidden, in contrast to the situation for bioactive LPS with its 
cubic aggregate structure31. However, since the cell activation is a membrane step and also a multilamellar LPS 
can incorporate into the immune cell membrane, cell receptors such as TLR4 may be blocked by them in this 
way inhibiting the cell signaling via bioactive LPS. A further observation in accordance to the chemical analysis 
described here should be mentioned: The periodicities in the range of 6.3 to 6.7 nm as shown in Fig. 9 are char-
acteristic also for multi-lamellar structures of LPS from rough mutant Re and/or Rd from Salmonella minnesota, 
which in a previous report33 were found to result from the addition of divalent cations such as Mg2+ or at low 
water content. The final structure of the TLR4 antagonist revealed that the particular molecule is a lipooligosac-
charide (LOS) and not a classical lipopolysaccharide (LPS).
Many TLR4 antagonists are based on LPS or lipid A structures obtained from non-pathogenic bacteria such 
as Rhodobacter capsulatus and Rhodobacter sphaeroides34. Compounds like E5531 (analogue of R. capsulatus 
lipid A) or Eritoran/E5564 (based on R. sphaeroides lipid A) were developed for the treatment of sepsis. In line 
with our results, Eritoran is significantly protective in animal models of sepsis35. In general, the TLR4 antagonists 
based on lipid A binds to MD-2 and thereby prevents binding of the agonist to the MD-2/TLR4 complex. This was 
interpreted to be due to the multilamellar aggregate structure of these antagonists which do not represent a dis-
turbance of the membrane architecture at the site of the receptors, in contrast to the behavior of the non-lamellar 
aggregate structures of hexaacylated agonistic LPS36. Our data show that B. quintana LPS has a similar mode of 
action as E5564. Recently, potent low molecular inhibitors of TLR4 have been reported that interfere with the 
TLR4-MD2 complex formation37.
Polymyxin B is an antibiotic primarily used for resistant Gram-negative infections and it is derived from the 
bacterium Bacillus polymyxa. It has a bactericidal action against almost all Gram-negative bacilli and polymyxin 
binds to the cell membrane and alters its structure, making it more permeable, resulting in death of the microbe. 
Polymyxin B is well known for its LPS neutralizing capacity in vitro. This can be correlated with the observation, 
that polymyxin B converts the aggregate structure of agonistic LPS into a multilamellar form38. In the case of 
B. quintana LPS, its aggregate structure is already multilamellar, and is not changed furthermore by polymyxin B 
Furthermore, the fluidization observed when PMB interacts with hexaacylated endotoxins is absent32,38.
Here we demonstrated that B. quintana LPS binds very rapidly to the TLR4 complex, within 15 minutes the 
B. quintana LPS prevents activation of TLR4. Even 2 h after E. coli LPS was added to the cell cultures, B. quintana 
LPS was able to prevent cytokine production. This delayed antagonistic effect was only reported for one other 
natural TLR4 antagonist, isolated from the cyanobacterium Oscillatoria planktothrix FP139. It was demonstrated 
that the LPS from this cyanobacterium could block DC maturation and activation even 6 h after E. coli LPS was 
added. In line with our report, the cyanobacterium LPS was able to prevent LPS/D-galactosamine induced lethal 
shock. Although, the dose needed for protection was much higher (750 μ g per mouse) than we showed in this 
current report (100 μ g per mouse), indicating the potency of B. quintana LPS.
Figure 7. B. quintana LPS suppressed LPS/D-galactosamine-induced lethal endotoxaemia. C57/Bl6 mice 
were i.p. injected with either PBS (n = 20) or 100 μ g B. quintana LPS (n = 20). After 30 minutes 10 mice of each 
group were injected i.p. with PBS and 10 mice were injected i.p. with E. coli LPS (1 μ g) + D-galactosamine 
(14 mg). Survival was monitored for 10 days. (A) Survival rate. (B) Area under the curve. ***p < 0.01, one-way 
ANOVA test.
www.nature.com/scientificreports/
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Figure 8. Proposed structure of B. quintana LPS. The primary sequence was depicted by Zähringer et al.57 
for the equivalent molecule of B. henselae. Gas chromatographic analysis and mass spectrometry present 
differences of the B. quintana in comparison to the B. henselae LPS in the sugar composition and the acyl 
chains. The former contains a N-acetylated hexose in the outer core, while for the latter a hexose is described. 
Furthermore, one of the 3-OH C12 fatty acids is unsaturated in the LPS of B. quintana. For both substitutions 
the structures are not elucidated yet and the drawing shows only one of several possible positions.
Figure 9. Small-angle X-ray scattering pattern of LPS from B. quintana at 20 and 40 °C. The logarithm of the 
scattering intensity log I is plotted versus the scattering vector s = 1/d (d spacings of the reflections.
www.nature.com/scientificreports/
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Activation of TLR4 has been associated with many inflammatory diseases and infectious complications40,41. 
Therefore, many efforts have been taken to develop or identity potent inhibitors of TLR4 for in-vivo applications. 
Apart from lipid A-derived structures or small molecules that interfere with MD-2/TLR4 formation42, antibodies 
have been developed. However, it seems that anti-TLR4 antibodies do not bind only TLR4, but via the Fc portion 
also to Fcγ Rs. This dual action of these anti-TLR4 antibodies may be of importance to target inflammatory cells 
that express both receptors43.
Apart from infectious agents that can trigger TLR4 signaling, several endogenous TLR4 ligands have 
been described in the recent years. Many damage-associated products (DAMP) and inflammatory media-
tors have been linked to TLR4 for their pro-inflammatory behavior. Most of these TLR4 ligands are released 
after cells or tissues have been activated or damaged. A few examples of these endogenous TLR4 ligands are 
HMBG1, S100A7/8, fibronectin extra domain A and fetuin7,44–47. Potent inhibitors of TLR4 that interfere 
with both microbial TLR4 ligands as well as endogenous TLR4 ligands binding to TLR4 will have significant 
therapeutic value. Since the most TLR4 inhibitors are based on the disruption of the TLR4/MD-2 complex, 
which is very specific for lipid A-derived compounds, it remains to be explored whether TLR4 antagonist 
can be generated that block both classes of TLR4 ligands. Of high interest, B. quintana LPS reveals to inhibit 
both exogenous and endogenous TLR4 as previously reported15,48. Further investigation is warranted to 
elucidate the structure of B. quintana LPS to obtain insight into the mode of action and the possibility 
to synthesize this potent TLR4 antagonist.
Materials and Methods
The authors confirm that all experiments were performed in accordance with relevant guidelines and regula-
tions. Written informed consents were obtained from all donors in accordance with the ethical principles set out 
in the declaration of Helsinki. The ethical review board of the Radboud University Medical Center, Nijmegen, 
The Netherlands, approved the study in which blood were used for healthy subjects (CMO2299 2010/104). The 
experimental protocols for murine studies were approved by the ethic committee for animal experiments (DEC) 
of the Radboud University Medical Center, Nijmegen, The Netherlands.
Reagents and microorganisms. LPS (E. coli serotype O55:B5) was purchased from Sigma Chemical Co 
and the Bartonella quintana CIP 103739 strain was kindly provided by Dr. Tanja Schulin and grown on sheep 
blood agar at 37 °C in a 5% CO2 atmosphere. B. quintana LPS was extracted by a two-step extraction method, 
which eliminates contamination with proteins. B. quintana LPS was extracted by hot phenol-water method as 
described previously23,49. Briefly, Bartonella quintana bacteria were scraped from blood agar plates, resuspended 
in PBS and heat-inactivated for 60 min in 56 °C. Thereafter, heat killed bacteria were wash twice with PBS and 
centrifuged for 10 min. at 16,262 × g. 2 grams of bacterial mass was used to isolate the LPS. Warm water (65 °C) 
was added to the pellet and the solution was vortexed for 10 minutes. Thereafter, the heated phenol (65 °C) was 
added and the solution was stirred for 2 hours at a temperature between 63–68 °C. Thereafter, solution was cen-
trifuged 4,435 × g for 40 min at 4 °C. The aqueous phase was collected and transferred to a dialysis cassette (3.500 
MWCO) and dialyzed against demi water in a 3L glass beaker in the cold room. The distilled water was changed 
after 30 minutes for the first time and then after 1 hour for 3–4 times. The LPS was dialyzed for two days at 4 °C, 
changing demi water 3 times a day. The dialyzed LPS was extracted and stored at − 80 °C for until lyophilizing. 
For re-purification, 5mg Bartonella quintana LPS was added to 1 ml 0.2% TEA (Triethylamine)/0.5% Na-DOC 
(Natrium deoxycholate). Thereafter, 1 ml warm (60 °C) phenol:water (9:1 V/V) was added and the solution was 
vortexed for 5 min. After separation of the phases (5 minutes at 4 °C) the solution was centrifuged for 40 min. 
at 6,652 × g (4 °C). The water phase was collected and transferred to new sterile 15 ml tube. To the first phe-
nol phase again 1 ml 0.2% TEA/0.5% Na-DOC was added and the previous steps were repeated. The second 
phenol phase was used to repeat the purification steps for the third time. The water phase of last 2 steps were 
combined with the first step. The LPS was dialyzed as described above, using the 3,500 MWCO cassette. To the 
dialyzed LPS drop-by-drop 1.5 ml of NaAc/EtOH (0.4 M in 100% EtOH) per each 0.5 ml of LPS was added and 
the solution was kept for 1 h on ice/water to let the LPS precipitate. Thereafter, the LPS was collected by centrif-
ugation (30 min. at 16,262 × g) and washed twice with 1.5 ml cold EtOH followed by centrifugation (30 min. at 
16,262 × g). Thereafter, LPS was dried on air, dissolved in PBS, aliquoted and stored by − 20 °C. E. coli LPS from 
Sigma was also double purified, as described above.
Isolation of PBMC and stimulation of cytokine production. Peripheral blood mononuclear cells 
(PBMCs) were isolated healthy individuals (written informed consent was obtained from all subjects), as 
described earlier50,51. Briefly, PBMCs were isolated by density gradient centrifugation using Ficoll-Paque PLUS 
(GE Healthcare) and collecting the white interphase. Next, PBMCs were washed twice in cold PBS and concen-
trations were adjusted to 5 × 106 cells/ml in RPMI-1640 Dutch Modified culture medium (RPMI supplemented 
with 2 mM l-glutamine, 1 mM pyruvate; GIBCO Invitrogen, Carlsbad, CA, USA). PBMC (5 × 105), in a volume 
of 100 μ l volume in round-bottomed 96-well plates (Greiner, Alphen a/d Rijn, The Netherlands), were incubated 
with either 100 μ l of culture medium (negative control) or one of the following stimuli: B. quintana LPS and 
E. coli LPS (10 ng/ml).
Measurement of cytokine concentrations. Cytokines were determined by commercially availa-
ble ELISA kits according to manufacturer’s instructions. Concentrations of human IL-1β , TNF-α , (R&D 
Systems, Inc., Minneapolis, MN, USA), IL-6 and IL-8 (Sanquin Reagents, Amsterdam, The Netherlands) were 
measured52,53.
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Animals. C57Bl/6J mice were purchased from Charles River (Sulzfeld, Germany). For the experiments, 8–12 
week old mice, weighing 20–25 g, were used. The animals were fed standard laboratory chow (Hope Farms, 
Woerden, The Netherlands) and housed under specific pathogen-free conditions. The experimental protocols 
were approved by the ethic committee for animal experiments (DEC) of the Radboud University Medical Center, 
Nijmegen, The Netherlands.
Experimental endotoxaemia model. The previously reported model of endotoxemia was used54. Briefly, 
20 wild type mice were injected intraperitoneally (i.p.) with either PBS, or B. quintana LPS 100 μ g/mouse. After 
30 minutes 10 mice of each group were injected with PBS and 10 mice were injected i.p. E. coli LPS 1 μ g per mouse 
(Escherichia coli LPS 055:B5 Sigma Chemical Co., St Louis, MI, USA) + D-galactosamine 14 mg per mouse. 
Survival of all 4 groups (PBS + PBS, B. quintana LPS + PBS, PBS + E. coli LPS/D-galactosamine and B. quintana 
LPS + E. coli LPS/D-galactosamine was assessed for 10 days.
Structural analysis of B. quintana LPS. The compositional analysis was done by using combined gas 
liquid chromatography and mass spectrometry (GLC-MS), as well as electrospray ionization mass spectrometry 
(ESI-MS). For the GLC-MS the B. quintana LPS was methanolyzed by 2 M HCL/CH3OH for 24 h at 85 °C and 
for the determination of the hexoses afterwards peracetylated or trimethylsilylated with N,O-bis(trimethylsilyl)
trifluoroacetamide for the fatty acids, respectively. The resulting compounds were analyzed in a GLC on a 
Hewlett-Packard HP 5890 Series II chromatograph, equipped with a 30-m fused silica SPB-5 column (Supelco) 
using a temperature gradient of 150 °C (3 min) → 320 °C at 5 °C/min, and GLC-MS on a Hewlett-Packard HP 
5989A instrument equipped with a 30-m HP-5MS column. Electrospray Ionization Fourier Transform Ion 
Cyclotron Resonance (ESI FT-ICR) MS was performed in using a hybrid Apex Qe FT-ICR MS instrument 
(Bruker Daltonics) in the negative ion mode, equipped with a 7 Tesla actively shielded magnet and an Apollo 
dual ion source55. Small-angle X-ray scattering (SAXS) measurements of LPS from Bartonella quintana were 
performed at the European Molecular Biology Laboratory outstation at the Hamburg synchrotron radiation 
facility (HASYLAB) using the double-focusing monochromator-mirror camera X33. Scattering patterns in the 
range of the scattering vector 0.01 < s < 1 nm−1 (s = 2 sinθ /λ , 2θ = scattering angle, λ = wavelength = 0.15 nm) 
were recorded at 20 and 40 °C with exposure times of 1 min using an image plate detector with online readout 
(MAR345; MarResearch, Norderstedt/Germany)56. The s-axis was calibrated with Ag-Behenate, which has a peri-
odicity of 5.84 nm. We evaluated the diffraction by assigning the spacing ratios of the main scattering maxima 
to defined three-dimensional structures. For this study, the multi-lamellar structures were the most relevant, for 
which characteristic spacing’s at the periodicity d and further reflections at d/2, d/3 etc. are found.
Statistical analysis. The data are expressed as mean ± SEM. Differences between experimental groups 
were tested using the two-sided Mann-Whitney U test or one-way ANOVA performed on GraphPad Prism 6.0 
software (GraphPad). P values of ≤ 0.05 were considered significant. The IC50 was calculated using non-linear 
concentration-response curve application within GraphPad Prism 6.0.
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